Mirae Asset Global Investments Co. Ltd. Buys 1,679 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Mirae Asset Global Investments Co. Ltd. grew its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 46.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,301 shares of the medical research company’s stock after acquiring an additional 1,679 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Charles River Laboratories International were worth $987,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in shares of Charles River Laboratories International in the 3rd quarter worth $79,000. Exchange Traded Concepts LLC boosted its position in shares of Charles River Laboratories International by 26.4% during the third quarter. Exchange Traded Concepts LLC now owns 6,049 shares of the medical research company’s stock valued at $1,191,000 after buying an additional 1,264 shares during the last quarter. Creative Planning increased its holdings in Charles River Laboratories International by 4.0% in the 3rd quarter. Creative Planning now owns 4,672 shares of the medical research company’s stock worth $920,000 after buying an additional 180 shares in the last quarter. Wolff Wiese Magana LLC purchased a new position in Charles River Laboratories International in the 3rd quarter worth about $32,000. Finally, Mitchell & Pahl Private Wealth LLC lifted its stake in Charles River Laboratories International by 5.0% during the 3rd quarter. Mitchell & Pahl Private Wealth LLC now owns 3,311 shares of the medical research company’s stock valued at $652,000 after acquiring an additional 157 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on CRL shares. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. The Goldman Sachs Group decreased their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Morgan Stanley reduced their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. Finally, JPMorgan Chase & Co. dropped their target price on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research report on Monday, February 3rd. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $200.79.

Charles River Laboratories International Stock Down 3.1 %

CRL opened at $154.93 on Wednesday. The stock has a market cap of $7.92 billion, a price-to-earnings ratio of 19.39, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The firm’s fifty day moving average is $178.90 and its 200 day moving average is $192.24. Charles River Laboratories International, Inc. has a fifty-two week low of $154.01 and a fifty-two week high of $275.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).